
    
      i) Obtain preliminary information on the association between important baseline and
      on-treatment factors and SVR in this patient population. Variables to be examined may include
      gender, age, advanced fibrosis or cirrhosis (F3 or F4 estimated by Fibroscan), baseline viral
      load, RVR, wk 8 viral load, end-of-treatment viral response.

      ii) Evaluate adverse events. iii) Evaluate viral resistance.
    
  